These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3295 related articles for article (PubMed ID: 29153898)

  • 1. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
    Wang L; Zhao D; Qin K; Rehman FU; Zhang X
    Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
    Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
    Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
    Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
    Wu S; Hu C; Wu F; Wu Y; Liu P
    Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
    Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
    Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
    Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 165.